Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Detailed price information for Greenwich Lifesciences Inc (GLSI-Q) from The Globe and Mail including charting and trades.
The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz Pharmaceuticals’ Ziihera. Or at least that appears to be the consensus following ...
Trastuzumab deruxtecan plus pertuzumab reduced the risk of disease progression or death by 44% compared with THP, with a median PFS of 40.7 months. The Food and Drug Administration (FDA) has approved ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
Enhertu and Perjeta combination approved for first-line treatment of HER2-positive breast cancer, with companion diagnostics for patient identification. DESTINY-Breast09 trial showed improved ...
NEW YORK – Roche said Monday that the US Food and Drug Administration has approved the company's Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and Ventana HER2 Dual ISH DNA Probe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results